SCHEMBL23792000

SCHEMBL23792000

CC(C)Cc1sc(NCC(NC(=O)Nc2ccccc2)C(=O)O)nc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 3/20 0.45
▸ MAPK1 P28482 1/20 0.44
▸ MEN1 O00255 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ MAPT P10636 4/20 0.40
▸ LMNA P02545 2/20 0.40
▸ PTGDR2 Q9Y5Y4 5/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ DHODH Q02127 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23792015 0.89 GRN (0.40) FPR2MAPK1MEN1KMT2ANPC1
SCHEMBL23782529 0.89 GRN (0.47) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL30173796 0.89 GRN (0.47) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL26240299 0.88 GRN (0.40) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL23792013 0.85 GRN (0.41) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL23791772 0.85 PTGDR2 (0.46) FPR2MEN1KMT2ANPC1RAB9A
SCHEMBL23792019 0.85 GRN (0.38) NPC1RAB9ALMNAPTGDR2POLB
SCHEMBL23782502 0.85 CTSK (0.42) PTGDR2DHODH
SCHEMBL23792017 0.84 MEN1 (0.41) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL23791724 0.84 DHODH (0.42) SMN1; SMN2NPC1RAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FPR2 3697/4885MAPK1 1701/4885MEN1 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback